← Human Trials & Peer-Reviewed Studies
EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: an observational longitudinal study in patients undergoing coronary artery bypass graft surgery
Plain-language guide to PMID 24727704 (2014): observational study of BNP (Nesiritide) in 365 patients.
Key Facts
- PMID
- 24727704
- Journal
- British journal of anaesthesia
- Year
- 2014
- Study type
- Observational Study
- Authors
- Holm J et al. (7 authors)
- DOI
- 10.1093/bja/aeu088
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this observational study publication.
As N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a predictor for postoperative heart failure, the aim was to evaluate if preoperative NT-proBNP could provide additional prognostic information to the recently launched EuroSCORE II.
To assess what clinical outcomes are indicated by NT-proBNP levels in different risk categories, the patients were stratified according to EuroSCORE II.
Who Took Part
The study group was 365 patients.
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.
Preoperative NT-proBNP and EuroSCORE II were evaluated with regard to severe circulatory failure after operation according to prespecified criteria.
How the Study Was Run
Based on receiver operating characteristics analysis, these cohorts were assessed with regard to preoperative NT-proBNP below or above 1028 ng litre(-1).
The follow-up time averaged 4.4 (0.7) yr.
What Was Measured
PubMed files the paper under topics including Acute Coronary Syndrome, Biomarkers, Coronary Artery Bypass, Hospital Mortality, Longitudinal Studies, Natriuretic Peptide, Brain and Peptide Fragments.
The authors tagged it with the keywords coronary artery bypass surgery, natriuretic peptides and risk assessment.
What This Means in Plain Language
This is an observational study of BNP (Nesiritide) in 365 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (British journal of anaesthesia), a journal based in England.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.